Opioids Prescriptions

Introduction. This is a SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified businesses interested and capable of providing the services described below. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The acquisition will be for 2 year and a total of ~ 24 months. Background. The Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and Office of Acquisition Services (OAS), on behalf of the Division of Health Informatics and Surveillance (DHIS) is seeking a qualified business to provide the capability through data and science to help identify better solutions for public health programs implementation. CDC is looking for a company which offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. CDC is looking to acquire and have direct access to large prescription data sets that also include clinical medical data such as diagnostics, co-morbid conditions, treatment and procedures in addition to patient demographics. This sources sought solicitation is focused on the characterization of opioids prescribing in the United States using commercially available prescribing data. Purpose. The purpose of this project is to address the Opioid epidemic. CDC needs to have access to the world's largest curated healthcare information source, advanced analytics, leading technologies and extensive industry knowledge across diseases, geographies and scientific methods. Objective. The objective is to obtain access to near real time data, prescription and clinical information at the national, regional, state, Metropolitan Statistical Area (MSA) and county-level on prescription drugs associated with high levels of misuse, morbidity, and mortality, specifically opioid analgesics and benzodiazepines Requirements. CDC is looking for a vendor that could supply the following: - A proven history of providing large, customized data sets to researchers focused on public health and specifically characterizing opioids use in the outpatient setting; - The ability to provide individual and customized data products that include: I. A nationally representative sample of outpatient opioids prescriptions filled in the United States; II. Ambulatory Electronic Medical Records representing visits to U.S. physicians that include details on diagnoses and prescriptions; III. Long-term care pharmacy data linkable to clinical data; IV. Comprehensive data on all medications prescribed in the United States, in multiple healthcare settings V. International prescribing data; - A Software-As-A-Service (SaaS) based platform to: - manage major Real World Evidence (RWE) datasets in one place, - lever consistent terminologies across countries (e.g., OMOP Common data model), - manage and interrogate data in a standard SaaS based software solution and perform various analytics in innovative visualizations such as understanding compliance, persistence, or Line of Therapy changes (advanced analytics), - provide an intuitive interface that enables both RWE experts and business users to interact with the data. - serve as a turnkey solution that put analytics in the hands of end users through intuitive visualizations - Key personnel, including analytic support, with experience in working with public health entities. - Senior staff will have been authors or co-authors on peer-reviewed publications using their available data sources to investigate and explore topics of interest to public health, including opioids utilization, overuse and adverse drug events